scholarly journals Cryptococcus neoformansas a Model for Radioimmunotherapy of Infections

2011 ◽  
Vol 2011 ◽  
pp. 1-11 ◽  
Author(s):  
Ekaterina Dadachova ◽  
Arturo Casadevall
Keyword(s):  
Monoclonal Antibodies ◽  
Infectious Diseases ◽  
Cancer Treatment ◽  
Cryptococcus Neoformans ◽  
Viral Infections ◽  
Model Organism ◽  
Laboratory Studies ◽  
Potential Toxicity ◽  
Novel Approaches ◽  
The Creation

There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeastCryptococcus neoformans(CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of “panantibodies” for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.

scholarly journals RECOMBINANT ANTIBODIES IN ANTI-VIRAL THERAPY: ACHIEVEMENTS AND PERSPECTIVES

2018 ◽  
pp. 114-123
Author(s):  
A. S. Oksanich ◽  
A. A. Nikonova ◽  
V. V. Zverev
Keyword(s):  
Monoclonal Antibodies ◽  
Infectious Diseases ◽  
Viral Infection ◽  
Viral Infections ◽  
Recombinant Antibodies ◽  
Viral Diseases ◽  
Large Group ◽  
Viral Therapy ◽  
Antibody Preparations ◽  
Anti Viral Therapy

More than 60 recombinant monoclonal antibodies (mAbs) have been developed for the treatment of various diseases in the last 20 years. About 30 antibody preparations are approved for use in therapy, including large group of drugs against cancer. In addition, mAbs are used in transplantation, for the treatment of cardiovascular, autoimmune and, in rare cases, infectious diseases. Despite the fact that tens millions of people die every year from viral diseases, only one drug based on recombinant antibodies for the prevention of RSV in children is currently allowed. This review focuses on approaches to generate therapeutic mAbs to fight viral infection, examples of mAb therapies for viral infections, and the challenges of developing such therapies.

scholarly journals Monoclonal Antibodies (mAbs) Approved for Cancer Treatment in the 2020s

2021 ◽  
Vol 1 (2) ◽  
Author(s):  
Pouya Safarzadeh Kozani ◽  
Abdolhossein Naseri ◽  
Pooria Safarzadeh Kozani ◽  
Sanaz Khatami ◽  
Abdolkarim Sheikhi
Keyword(s):  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Cancer Treatment ◽  
Solid Tumors ◽  
Viral Infections ◽  
Clinical Use ◽  
Wide Applicability ◽  
Wide Range

: Monoclonal antibodies are one of the most eminent types of immunotherapeutics that have taken over the biopharmaceutical market because they are approved for a wide range of cancers, either blood-based malignancies or solid tumors, and also non-cancer indications, from migraine to viral infections. Due to their wide applicability as immunotherapeutics, countless biopharmaceutical companies try to be in the competition by developing monoclonal antibodies and advancing into clinical trials with them. Since the approval of the first monoclonal antibodies, the speed of their discovery and approval for medical use have been rather incremental, so that the progress of this market has been anticipated to increase in the current decade. Herein, we take a look at some of the monoclonal antibodies, which have been approved for clinical use in the current decade, so far. Moreover, we underline the encouraging results from the clinical trials that led to the approval of these immunotherapeutics.

Treatment of ebola and other infectious diseases: melatonin “goes viral”

2020 ◽  
Vol 3 (1) ◽  
pp. 43-57 ◽  
Author(s):  
Russel J Reiter ◽  
Qiang Ma ◽  
Ramaswamy Sharma
Keyword(s):  
Mortality Rate ◽  
Infectious Diseases ◽  
Hemorrhagic Shock ◽  
Safety Profile ◽  
Ebola Virus ◽  
Viral Infections ◽  
Virus Disease ◽  
Attractive Potential ◽  
Potential Treatment

This review summarizes published reports on the utility of melatonin as a treatment for virus-mediated diseases. Of special note are the data related to the role of melatonin in influencing Ebola virus disease. This infection and deadly condition has no effective treatment and the published works documenting the ability of melatonin to attenuate the severity of viral infections generally and Ebola infection specifically are considered. The capacity of melatonin to prevent one of the major complications of an Ebola infection, i.e., the hemorrhagic shock syndrome, which often contributes to the high mortality rate, is noteworthy. Considering the high safety profile of melatonin, the fact that it is easily produced, inexpensive and can be self-administered makes it an attractive potential treatment for Ebola virus pathology.  

Antibody Therapy for the Control of Viral Diseases: An Update

2019 ◽  
Vol 20 (13) ◽  
pp. 1108-1121 ◽  
Author(s):  
Miriam Dibo ◽  
Eduardo C. Battocchio ◽  
Lucas M. dos Santos Souza ◽  
Matheus D. Veloso da Silva ◽  
Bruna K. Banin-Hirata ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Viral Antigen ◽  
Viral Infections ◽  
Antibody Therapy ◽  
Therapeutic Strategies ◽  
Viral Diseases ◽  
Specific Antibodies ◽  
The Status ◽  
Epidemiological Impact

The epidemiological impact of viral diseases, combined with the emergence and reemergence of some viruses, and the difficulties in identifying effective therapies, have encouraged several studies to develop new therapeutic strategies for viral infections. In this context, the use of immunotherapy for the treatment of viral diseases is increasing. One of the strategies of immunotherapy is the use of antibodies, particularly the monoclonal antibodies (mAbs) and multi-specific antibodies, which bind directly to the viral antigen and bring about activation of the immune system. With current advancements in science and technology, several such antibodies are being tested, and some are already approved and are undergoing clinical trials. The present work aims to review the status of mAb development for the treatment of viral diseases.

scholarly journals Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Camille Zenobia ◽  
Karla-Luise Herpoldt ◽  
Marcelo Freire
Keyword(s):  
Infectious Diseases ◽  
Oral Mucosa ◽  
Viral Infections ◽  
Emerging Infectious Diseases ◽  
Humoral Response ◽  
Outer Membrane Vesicles ◽  
Oral Microbiome ◽  
Microbial Pathogens ◽  
Cell Mediated Immunity ◽  
Th17 Response

AbstractMucosal tissues act as a barrier throughout the oral, nasopharyngeal, lung, and intestinal systems, offering first-line protection against potential pathogens. Conventionally, vaccines are applied parenterally to induce serotype-dependent humoral response but fail to drive adequate mucosal immune protection for viral infections such as influenza, HIV, and coronaviruses. Oral mucosa, however, provides a vast immune repertoire against specific microbial pathogens and yet is shaped by an ever-present microbiome community that has co-evolved with the host over thousands of years. Adjuvants targeting mucosal T-cells abundant in oral tissues can promote soluble-IgA (sIgA)-specific protection to confer increased vaccine efficacy. Th17 cells, for example, are at the center of cell-mediated immunity and evidence demonstrates that protection against heterologous pathogen serotypes is achieved with components from the oral microbiome. At the point of entry where pathogens are first encountered, typically the oral or nasal cavity, the mucosal surfaces are layered with bacterial cohabitants that continually shape the host immune profile. Constituents of the oral microbiome including their lipids, outer membrane vesicles, and specific proteins, have been found to modulate the Th17 response in the oral mucosa, playing important roles in vaccine and adjuvant designs. Currently, there are no approved adjuvants for the induction of Th17 protection, and it is critical that this research is included in the preparedness for the current and future pandemics. Here, we discuss the potential of oral commensals, and molecules derived thereof, to induce Th17 activity and provide safer and more predictable options in adjuvant engineering to prevent emerging infectious diseases.

Comparative gene genealogical analyses of strains of serotype AD identify recombination in populations of serotypes A and D in the human pathogenic yeast Cryptococcus neoformans

Microbiology ◽  
2003 ◽  
Vol 149 (8) ◽  
pp. 2147-2154 ◽  
Author(s):  
Jianping Xu ◽  
Thomas G. Mitchell
Keyword(s):  
Monoclonal Antibodies ◽  
Cryptococcus Neoformans ◽  
Natural Populations ◽  
The Other ◽  
Pathogenic Yeast ◽  
Gene Genealogy ◽  
Serotype A ◽  
The World ◽  
Significant Divergence ◽  
Allelic Group

Cryptococcus neoformans is a major pathogen of humans throughout the world. Using commercial monoclonal antibodies to capsular epitopes, strains of C. neoformans manifest five serotypes: A, B, C, D and AD. Previous studies demonstrated significant divergence among serotypes A, B, C and D, which are typically haploid. In contrast, most strains of serotype AD are diploid or aneuploid and result from recent hybridization between strains of serotypes A and D. Whether serotypes A, B, C and D represent strictly asexual lineages is not known. Using comparative genealogical analyses of two genes, the authors investigated whether recombination occurred among strains within serotypes A and D. For each of 14 serotype AD strains, a portion (642 bp) of the orotidine monophosphate pyrophosphorylase (URA5) gene was cloned and sequenced. Each of these 14 strains contained two different alleles and sequences for both alleles were obtained. The URA5 gene genealogy was compared to that derived from the laccase (LAC) gene, which was reported recently for the same 14 strains. For both genes, each of the 14 serotype AD strains contained two phylogenetically distinct alleles: one allele was highly similar to those from serotype A strains and the other to alleles from serotype D strains. However, within both the serotype A allelic group and the serotype D allelic group, there was significant incongruence between genealogies derived from URA5 and LAC. The results suggest recombination in natural populations of both serotypes A and D.

Role of cannabinoids in various diseases: A review

2021 ◽  
Vol 23 ◽  
Author(s):  
Simran Kaur ◽  
Nikita Sharma ◽  
Arpita Roy
Keyword(s):  
Infectious Diseases ◽  
Metabolic Disorders ◽  
Viral Infections ◽  
Cannabis Sativa ◽  
Endocannabinoid System ◽  
Psychological Disorders ◽  
Bioactive Compound ◽  
The Body ◽  
Therapeutic Aspect

Background: The plant, Cannabis sativa is heavily explored and researched with many industrial and pharmaceutical applications. The medicinal and therapeutic role of cannabis Sativa has been summarized in the paper, citing its mechanism of action and influence on the human body. Diseases like metabolic disorders, infectious diseases, and psychological disorders pose negative and long-term drastic effects on the body like neurodegeneration and other chronic system failures. Several existing literature has proved its effectiveness against such diseases. Objectives: This review aims to provide an overview of the role of cannabinoids in various diseases like metabolic disorders, infectious diseases, and psychological disorders. Method: Various e-resources like Pubmed, Science Direct, and Google Scholar were thoroughly searched and read to form a well-informed and information-heavy manuscript. Here we tried to summaries the therapeutic aspect of Cannabis sativa and its bioactive compound cannabinoids in various diseases. Result: This review highlights the various constituents which are present in Cannabis sativa, the Endocannabinoid system, and the role of cannabinoids in various diseases Conclusion: Recent research on Cannabis has suggested its role in neurodegenerative diseases, inflammation, sleep disorders, pediatric diseases, and their analgesic nature. Therefore, the authors majorly focus on the therapeutic aspect of Cannabis sativa in various diseases. The focus is also on the endocannabinoid system (ECS) and its role in fighting or preventing bacterial, parasitic, fungal, and viral infections.

Consensus ‘Interferon therapy for patients with influenza, SARS and COVID19’

2021 ◽  
pp. 51-58
Author(s):  
N. D. Yushchuk ◽  
I. V. Maev ◽  
A. L. Vertkin
Keyword(s):  
General Practitioner ◽  
Infectious Diseases ◽  
Secondary Prevention ◽  
Interferon Therapy ◽  
Viral Infections ◽  
Total Duration ◽  
Community Acquired Pneumonia ◽  
Outpatient Clinics ◽  
Primary Contact ◽  
Respiratory Viral Infections

According to the who, the share of acute respiratory viral infections (амма? and influenza) accounts for about 90–95% of all infectious diseases; in russia, influenza and arvi take up to 40% of the total duration of official disability, which determines the significance of this pathology. At the same time, the primary contact of the overwhelming majority of patients with suspected arvi and influenza occurs with a therapist or general practitioner of polyclinics. The proposed consensus of experts is intended to systematize the known approaches to the diagnosis, treatment and secondary prevention of influenza, acute respiratory viral infections and community-acquired pneumonia for their use at outpatient clinics. The schemes of using interferon therapy for arvi and influenza are considered in detail.

The role of PCSK9 in infectious diseases.

2021 ◽  
Vol 28 ◽  
Author(s):  
Laura Magnasco ◽  
Chiara Sepulcri ◽  
Roberta Maria Antonello ◽  
Stefano Di Bella ◽  
Laura Labate ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Malaria Infection ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Physiological Role ◽  
Protective Role ◽  
Loss Of Function ◽  
Pcsk9 Inhibition ◽  
Sepsis And Septic Shock

Background: In recent years, many aspects of the physiological role of PCSK9 have been elucidated, particularly regarding its role in lipid metabolism, cardiovascular risk, and its role in innate immunity. Increasing evidence is available about the involvement of PCSK9 in the pathogenesis of viral infections, mainly HCV, and the regulation of host response to bacterial infections, primarily sepsis and septic shock. Moreover, the action of PCSK9 has been investigated as a crucial step in the pathogenesis of malaria infection and disease severity. Objective: This paper aims to review the available published literature on the role of PCSK9 in a wide array of infectious diseases. Conclusion: Besides the ongoing investigation on PCSK9 inhibition among HIV-infected patients to treat HIV- and ART-related hyperlipidemia, preclinical studies indicate how PCSK9 is involved in reducing the replication of HCV. Interestingly, high plasmatic PCSK9 levels have been described in patients with sepsis. Moreover, a protective role of PCSK9 inhibition has also been proposed against dengue and SARS-CoV-2 viral infections. Finally, a loss of function in the PCSK9-encoding gene has been reported to reduce malaria infection mortality.

Sign in / Sign up

Export Citation Format

Share Document